There are multiple strategies for therapeutically targeting tumor hypoxia including hypoxia activated prodrugs (HAPs), inhibitors of HIF-1, HIF-2, and inhibitors of the associated signaling pathways. This evidence concerns the gene HIF1A and neoplasm.